- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Ipca Laboratories will merge with Krebs Biochemicals & Industries to drive operational synergies, optimize costs, and secure key API supplies. The move will also leverage Krebs' fermentation capabilities with Ipca's financial strength to expand into new APIs, benefiting Krebs which has been incurring losses. Shareholders of Krebs will receive 7 Ipca shares (Re. 1 each) for every 200 Krebs shares (Rs. 10 each). This results in a minor promoter shareholding reduction in Ipca from 44.72% to 44.66%. The Board has approved the scheme, which awaits necessary approvals.